Your browser doesn't support javascript.
loading
Monitoring the Patient with Retinal Angiopathy Associated with Hereditary Transthyretin Amyloidosis: Current Perspectives.
Marques, João Heitor; Coelho, João; Menéres, Maria João; Melo Beirão, João.
Afiliação
  • Marques JH; Serviço de Oftalmologia, Centro Hospitalar Universitário do Porto, Porto, Portugal.
  • Coelho J; Serviço de Oftalmologia, Centro Hospitalar Universitário do Porto, Porto, Portugal.
  • Menéres MJ; Serviço de Oftalmologia, Centro Hospitalar Universitário do Porto, Porto, Portugal.
  • Melo Beirão J; Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.
Clin Ophthalmol ; 16: 2227-2233, 2022.
Article em En | MEDLINE | ID: mdl-35844663
ABSTRACT
Retinal angiopathy associated with hereditary transthyretin amyloidosis (ATTRv), if untreated, may lead to irreversible vision loss. Our purpose was to systematically review the clinical and imaging features of retinal angiopathy associated with ATTRv and assemble a monitoring approach for these patients. All types of original research studies reporting clinical and imaging findings on retinal angiopathy associated with ATTRv were included. The most common clinical findings were tortuous retinal vessels, microaneurysms, retinal hemorrhages, sheathing of retinal vessels, whitish amyloid deposits along retinal arteries, obliteration of retinal vessels, vitreous hemorrhage, retinal and iris neovascularization. The most relevant imaging findings were hyperautofluorescence of perivessel amyloid deposits; delayed arterial filling, vascular leakage, and retinal ischemia on fluorescein angiography; late hypercyanescence along the choroidal arteries on indocyanine green angiography; perivascular hyperreflective material, needle-shaped deposits on the retinal surface and macular edema on optical coherence tomography (OCT) and attenuated retinal vascular network on OCT-angiography. ATTRv patients should be strictly followed to detect and treat retinal angiopathy, avoiding complications. Both panretinal photocoagulation and intravitreal anti-vascular endothelial growth factor have been used to treat retinal angiopathy in ATTRv. In an individual that presents with retinal angiopathy of unknown etiology, ATTRv should be considered as in the differential diagnosis, even out of the initial core countries. The prognostic value of subclinical findings, namely in OCT-A, is not yet established.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article